Payment overview · 2025
General Payments
$438.81
25 reported records · 13 companies
Healthcare provider profile · identity verified
Michael D. Harder, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX CITY, IA · NPI 1427064146
Verified facts
What the public records show
CMS Open Payments records show Michael D. Harder, D.O. received $438.81 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $69.95 | 15.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.22 | 14.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.11 | 13.5% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.60 | 8.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.15 | 8.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.14 | 7.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.84 | 6.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21.62 | 4.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.99 | 4.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.31 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.31 | 4.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.44 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.13 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $438.81 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.95 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $65.22 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.32 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.34 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 86 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 853 | 209 |
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 106 |
| Metformin Hcl | Metformin Hcl | 301 | 76 |
| Lisinopril | Lisinopril | 289 | 84 |
| Omeprazole | Omeprazole | 287 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 54 |
| Simvastatin | Simvastatin | 181 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 51 |
| Losartan Potassium | Losartan Potassium | 165 | 41 |
| Glipizide Er | Glipizide | 154 | 33 |
| Furosemide | Furosemide | 151 | 49 |
| Sertraline Hcl | Sertraline Hcl | 144 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 45 |
| Potassium Chloride | Potassium Chloride | 138 | 42 |
| Gabapentin | Gabapentin | 132 | 33 |
| Allopurinol | Allopurinol | 129 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 30 |
| Warfarin Sodium | Warfarin Sodium | 120 | 18 |
| Montelukast Sodium | Montelukast Sodium | 109 | 21 |
| Spironolactone | Spironolactone | 103 | 28 |
| Eliquis | Apixaban | 86 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 13 |
| Finasteride | Finasteride | 73 | 18 |
| Atenolol | Atenolol | 71 | 20 |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 23 |
| Carvedilol | Carvedilol | 69 | 17 |
| Tramadol Hcl | Tramadol Hcl | 62 | 30 |
| Ezetimibe | Ezetimibe | 60 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 18 |
| Alendronate Sodium | Alendronate Sodium | 58 | 16 |
| Prednisone | Prednisone | 57 | 40 |
| Valsartan | Valsartan | 57 | 17 |
| Chlorthalidone | Chlorthalidone | 55 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 23 |
| Gemfibrozil | Gemfibrozil | 52 | 13 |
| Trazodone Hcl | Trazodone Hcl | 52 | 11 |
| Bupropion Xl | Bupropion Hcl | 51 | 17 |
| Ozempic | Semaglutide | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Lorazepam | Lorazepam | 47 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 29 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 12 |
| Glipizide | Glipizide | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | 13 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 37 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Alprazolam | Alprazolam | 36 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Meloxicam | Meloxicam | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 20 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 12 |
| Sulindac | Sulindac | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Acetylcysteine | Acetylcysteine | 15 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 12 |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 11 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $438.81 · 25 records | ABBVIE INC. | AREXVY, ARISTADA, BEXSERO, CAMZYOS, CAPLYTA, ELIQUIS, EVENITY, FANAPT, JARDIANCE, KEVEYIS, Kerendia, LYBALVI, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error